PQRS

With more than 250 quality measures and several reporting methods to choose from, your practice may be challenged by finding a PQRS path that will yield the best results. Many providers participate to simply avoid a penalty, but a more sophisticated approach is to take into consideration your specialty, relevant measures, EHR capabilities, practice workflow, and results from previous participation. You want to ensure the metrics that result from your program are an accurate depiction of your center’s quality of care.

Choose from various options to report PQRS — see the table below. Notice how methods vary by practice size.

Generally speaking, PQRS requires that eligible providers report on nine quality measures that cover at least three National Quality Strategy domains. Although there is technically no threshold for performance rates on these measures, performance will play a much bigger role in determining a practice’s value-based modifier.

PQRS

Contact Miraca Life Sciences to learn how Miraca can assist your practice.
Call 1.855.347.7284 or email EHRPath@MiracaLS.com

I would recommend a Miraca Life Sciences and EMA partnership highly and without reservation.
— Martha J. Maso, MD, MPH,
Dermatologist, Westwood Dermatology Group, Westwood, N.J.


READ MORE
Learn about Miraca's unmatched quality. We provide our clients with access to the highest quality AP services.

Recent News


May 22, 2017

Miraca Life Sciences Again Expands Therapeutic Drug Monitoring with Addition of First Biosimilar Inflectra®

IRVING, Texas, May 23, 2017 — Miraca Life Sciences, the largest U.S. independent anatomic pathology laboratory, has further expanded its InformTx™ therapeutic drug monitoring (TDM) capabilities with the addition of testing for Inflectra® (infliximab-dyyb), which is the first biosimilar drug in the test offering. Since launching InformTx in June 2016, Miraca Life Sciences has expanded the service from four to […]

Continue reading


April 18, 2017

Miraca Research News: Philips receives FDA clearance to market Philips IntelliSite Pathology Solution for primary diagnostic use in the US

Pathologists at Miraca Life Sciences contributed significantly in the development of a new product from Philips, the IntelliSite Pathology Solution. As one of four clinical study sites, Miraca Life Sciences participated in “one of the largest studies ever conducted to directly compare the use of digital pathology to optical microscopes.” At Miraca, participation in the Philips study was a project of Miraca […]

Continue reading


April 11, 2017

Ten Research Projects from Miraca Life Sciences Accepted for DDW Conference

IRVING, Texas, April 12, 2017 — Ten research projects from the GI pathologists at Miraca Life Sciences, the nation’s largest independent anatomic pathology lab, have been accepted for presentation at the Digestive Disease Week® conference (DDW), which will be held May 6–9 in Chicago. DDW is the world’s largest gathering of physicians, researchers and industry in the fields of gastroenterology, […]

Continue reading


March 27, 2017

Simponi® is Sixth Drug in InformTx™ Therapeutic Drug Monitoring Service from Miraca Life Sciences

IRVING, Texas, March 28, 2017 — Miraca Life Sciences, the largest U.S. independent anatomic pathology laboratory, continues to expand its InformTx™ therapeutic drug monitoring (TDM) capabilities, now testing for Simponi (golimumab) as well as patient-developed antibodies to Simponi. This is the first TDM assay available in the United States for Simponi. With this addition, Miraca Life Sciences now performs TDM […]

Continue reading


November 30, 2016

Stelara® Now Available for Therapeutic Drug Monitoring from Miraca Life Sciences

IRVING, Texas, December 1, 2016 — Miraca Life Sciences, the largest U.S. independent anatomic pathology lab, has expanded its InformTx™ therapeutic drug monitoring service for drugs that treat inflammatory bowel disease (IBD) with the addition of Stelara (ustekinumab).

Miraca Life Sciences continues to perform therapeutic drug monitoring (TDM) for Remicade® (infliximab), Humira® (adalimumab), Cimzia® (Certolizumab pegol) and Entyvio® (vedolizumab). Since […]

Continue reading